Epilepsy

# Revolutionizing Drug Discovery with Advanced Electrophysiology

Understanding Epilepsy Through Precise MEA Technology

Epilepsy is a complex neurological disorder marked by recurrent seizures due to abnormal electrical activity in the brain. VitroVo’s cutting-edge electrophysiology assays provide deep insights into epilepsy mechanisms and drug efficacy using advanced Microelectrode Array (MEA) technology. Our platform allows researchers to model seizure dynamics, assess neurotoxicity, and predict drug responses with unparalleled precision.

VitroVo’s Approach to Epilepsy Research

At VitroVo, we combine over 20 years of experience in MEA technology with our advanced AI-powered analytics to transform epilepsy research. Our high-resolution MEA assays enable detailed analysis of neural network activity, seizure prediction, and the impact of compounds on neurophysiological health. By utilizing iPSC-derived neurons and brain organoids, we provide realistic disease models to better understand epilepsy and evaluate potential treatments.

Key Benefits of VitroVo’s Epilepsy Drug Discovery Platform

  • Accurate Seizure Modeling: Our Ultra-HD-MEA platform with 240K electrodes allows for single-cell resolution and in-depth analysis of seizure-induced activity in iPSC-derived neurons.

  • Predictive Drug Screening: Use our AI-powered analytics to predict the seizuregenic potential of drug candidates, offering insights comparable to in vivo studies while reducing experimental animal use.

  • Customizable Assays: Tailored assays for studying neural excitability and compound efficacy across a variety of epilepsy-related disease models, including Dravet Syndrome and temporal lobe epilepsy.

How VitroVo’s Capabilities Enhance Epilepsy Research

VitroVo’s MEA technology and advanced analytics are at the forefront of epilepsy drug discovery. By combining high-resolution electrophysiology, multi-parameter data analysis, and neuroscience modeling, we provide a powerful platform to accelerate the development of epilepsy treatments. Our customized assays enable high-throughput screening for drug candidates, while our integrated technologies maximize data extraction from a single experiment, ensuring more reliable and efficient drug testing.

  • Longitudinal Data Analysis: Utilize our ability to analyze long-term effects on neural activity, synaptic plasticity, and network synchronization to ensure the stability of drug effects.

  • Reduced Animal Testing: Benefit from our in-vitro models, which provide comprehensive data without the ethical concerns of animal testing, making research both cost-effective and ethically sound.

Contact Us:

Reach out to our team today to learn how VitroVo can support your Epilepsy research needs with unparalleled precision and reliability.

Assays

See assay examples below to find out how VitroVo can advance your Epilepsy research

In Vitro EEG for Seizure Liability & Antiepileptic Drug Screening
In Vitro EEG for Seizure Liability & Antiepileptic Drug Screening

Explore how in vitro EEG analysis of brain organoids coupled with microelectrode arrays (MEA) provides a reliable method for assessing seizure liability and screening antiepileptic drugs. Discover insights into drug safety and neuropharmacology.
First Direct MEA Recording of Human Astrocyte Activity for Drug Assessment
First Direct MEA Recording of Human Astrocyte Activity for Drug Assessment

Discover a groundbreaking method for recording spontaneous human astrocyte activity using microelectrode arrays (MEA). This study introduces a novel low-frequency analysis approach to assess astrocytic slow oscillations and seizurogenic drug responses, paving the way for advanced in vitro drug screening.
Unrivaled Synaptic Activity Mapping with High-Density CMOS-MEA
Unrivaled Synaptic Activity Mapping with High-Density CMOS-MEA

Discover how our high-density CMOS-MEA with 236,880 electrodes enables unprecedented resolution in synaptic activity analysis. Explore insights into drug-induced changes in excitatory and inhibitory neural connections at single-cell precision.
High-Density CMOS-MEA | Single-Cell Resolution for Drug Response Analysis
High-Density CMOS-MEA | Single-Cell Resolution for Drug Response Analysis

Discover how high-density CMOS-MEA with 236,880 electrodes enables unprecedented single-cell resolution for drug response evaluation in hiPSC-derived cortical neurons. Gain deeper insights into seizure liability and neural network function.